http://urologytimes.modernmedicine.com/urologytimes/Prostate+Cancer/Article/list/9395 News and developments in prostate cancer treatment, diagnosis, and research. 2009-11-21T08:32:22Z http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Low-risk-prostate-cancer-well-managed-with-active-/ArticleStandard/Article/detail/637932?contextCategoryId=9395&ref=25 Patients in active surveillance for prostate cancer were almost 20 times more likely to die of causes other than prostate cancer. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637932null XML http://urologytimes.modernmedicine.com/urologytimes/News/Diabetes-found-to-protect-against-prostate-cancer/ArticleStandard/Article/detail/638682?contextCategoryId=9395&ref=25 Cardiometabolic disorders and urologic disease represent a "perfect storm" of ailments, according to Kevin T. McVary, MD, who discusses the urologist's role in management. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452009/638682null REMOTE http://urologytimes.modernmedicine.com/urologytimes/Prostate+Cancer/Low-risk-prostate-cancer-well-managed-with-active-/ArticleStandard/Article/detail/638692?contextCategoryId=9395&ref=25 Drs. Scott B. Shappell and Leonard S. Marks discuss clinical use of urine PCA3 mRNA testing for prostate cancer. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452009/638692null REMOTE http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Post-radical-prostatectomy-PDE-5-therapy-speeds-er/ArticleStandard/Article/detail/637933?contextCategoryId=9395&ref=25 Postoperative pharmacologic therapy enhances the chances of erectile function recovery in virtually all categories of men who undergo bilateral nerve-sparing prostatectomy. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637933null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Prostate-cancer-radiation-therapy-may-increase-rec/ArticleStandard/Article/detail/637929?contextCategoryId=9395&ref=25 Compared with the general population, prostate cancer patients treated with radiation therapy were almost twice as likely to develop rectal cancer. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637929null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Benign-PSA-enhances-prostate-cancer-detection/ArticleStandard/Article/detail/637942?contextCategoryId=9395&ref=25 Benign PSA, measured in serum with a proprietary automated assay, improves prostate cancer detection when it is incorporated into an artificial neural network. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637942null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Diabetes-found-to-protect-against-prostate-cancer/ArticleStandard/Article/detail/637928?contextCategoryId=9395&ref=25 A diagnosis of diabetes or cardiometabolic disorders was not associated with an increased risk of incident prostate cancer, but rather a decreased incidence of the disease. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637928null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Study-Robotic-prostatectomy-safe-in-obese-patients/ArticleStandard/Article/detail/637944?contextCategoryId=9395&ref=25 Robotic prostatectomy in morbidly obese men is feasible, reasonably safe, and appears to provide oncologic control comparable to that achieved in a normal weight population. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637944null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Robot-assisted-radical-prostatectomy-Recent-techni/ArticleStandard/Article/detail/637931?contextCategoryId=9395&ref=25 Since the original description of the robot-assisted laparoscopic prostatectomy technique in 2002, several technical modifications have been reported. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637931null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Large-scale-study-PCa-patients-on-hormone-therapy-/ArticleStandard/Article/detail/633446?contextCategoryId=9395&ref=25 Hormone therapy used for the treatment of men with advanced prostate cancer is associated with an increased risk of developing various heart problems, according to findings from a study being called the largest and most comprehensive to examine this issue. 2009-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422009/633446null HTML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Enzyme-inhibitor-effective-against-refractory-pros/ArticleStandard/Article/detail/633623?contextCategoryId=9395&ref=25 In heavily pretreated men with castration-resistant prostate cancer, a specific and irreversible inhibitor of the enzyme CYP17 promotes declines in levels of PSA and the number of circulating tumor cells and an improvement in performance status. 2009-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422009/633623null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Vessel-sealing-devices-safe-for-nerve-sparing-radi/ArticleStandard/Article/detail/633625?contextCategoryId=9395&ref=25 The temperature spread of blood vessel-sealing devices is limited during radical prostatectomy, meaning that these devices can be used safely for nerve-sparing procedures, provided that the right precautions are taken. 2009-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422009/633625null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Monoclonal-antibodies-show-antitumor-efficacy-in-p/ArticleStandard/Article/detail/633618?contextCategoryId=9395&ref=25 Two monoclonal antibodies have demonstrated antitumor activity in clinical trials of men with castrate-resistant prostate cancer. 2009-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422009/633618null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/PCA3-Predictive-performance-superior-to-PSA-fPSA/ArticleStandard/Article/detail/633613?contextCategoryId=9395&ref=25 Researchers are further exploring the diagnostic and prognostic utility of PCA3, and data showed that combining PCA3 with free PSA and other risk factors significantly improves the accuracy for predicting biopsy outcomes. 2009-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422009/633613null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Researchers-find-virus-in-malignant-prostate-cance/ArticleStandard/Article/detail/627605?contextCategoryId=9395&ref=25 Researchers have reported that a virus known to cause leukemia and sarcomas in animals has been found in malignant human prostate cancer cells. 2009-09-24T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/382009/627605null HTML http://urologytimes.modernmedicine.com/urologytimes/Prostate+Cancer/Outcomes-improving-for-conservative-management-of-/ArticleStandard/Article/detail/627604?contextCategoryId=9395&ref=25 A comparison of outcomes of different eras of conservative treatment for localized prostate cancer indicates that overall and prostate cancer-specific survival rates are higher for men diagnosed from 1992 to 2002 compared with men diagnosed in the 1970s and 1980s. 2009-09-24T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/382009/627604null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Hormone-therapy-in-men-with-PCa-heart-conditions-r/ArticleStandard/Article/detail/625213?contextCategoryId=9395&ref=25 Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to researchers at Brigham & Women's Hospital-Dana Farber Cancer Institute, Boston. 2009-09-10T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/625213null HTML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Agent-markedly-improves-bone-mineral-density-in-an/ArticleStandard/Article/detail/624482?contextCategoryId=9395&ref=25 Twice-yearly injections of denosumab improved bone mineral density in men with prostate cancer treated with androgen deprivation therapy. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624482null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Three-fourths-of-men-with-prostate-cancer-may-be-e/ArticleStandard/Article/detail/624472?contextCategoryId=9395&ref=25 Due to PSA screening practices in the U.S., three-fourths of American men with prostate cancer may be eligible for focal ablation. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624472null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Radiation-dose-key-to-lasting-brachytherapy-effect/ArticleStandard/Article/detail/624461?contextCategoryId=9395&ref=25 Permanent brachytherapy's long-term success depends on delivery of a high biological effective dose of radiation. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624461null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Neoadjuvant-chemo-combo-no-silver-bullet-in-prosta/ArticleStandard/Article/detail/624480?contextCategoryId=9395&ref=25 In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624480null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Laparoscopic-radical-prostatectomy-Cure-is-more-li/ArticleStandard/Article/detail/624475?contextCategoryId=9395&ref=25 Laparoscopic radical prostatectomy has a definite learning curve, but it is slower than the learning curve for open surgery and is worsened in surgeons with prior open training. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624475null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/High-intensity-focused-ultrasound-shows-acceptable/ArticleStandard/Article/detail/624478?contextCategoryId=9395&ref=25 A single session of high-intensity focused ultrasound as primary therapy for localized prostate cancer results in an acceptable rate of biochemical-free recurrence. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624478null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Brachytherapy-vs-radical-prostatectomy-Efficacy-is/ArticleStandard/Article/detail/624486?contextCategoryId=9395&ref=25 Brachytherapy and radical prostatectomy are effective treatments for localized prostate cancer, but have different long-term functional effects, 13-year follow-up data show. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624486null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Studies-High-intensity-focused-ultrasound-yields-s/ArticleStandard/Article/detail/624479?contextCategoryId=9395&ref=25 Two of several studies presented by the same international team suggest that high-intensity focused ultrasound provides good biochemical-free survival at 5 years in patients treated in the absence of hormone therapy. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624479null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/New-tool-may-improve-quality-of-life-assessment-in/ArticleStandard/Article/detail/624470?contextCategoryId=9395&ref=25 A new computerized tool may solve the problem of the time and effort it takes to have patients fill out forms to assess quality of life. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624470null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Neoadjuvant-hormonal-therapy-yields-no-difference-/ArticleStandard/Article/detail/624489?contextCategoryId=9395&ref=25 Despite bringing lower rates of positive surgical margins and lower PSA nadirs, long-term neoadjuvant hormonal therapy did not lead to a difference in rates of PSA recurrence after 7 years. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624489null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Full-partial-cryoablation-Good-5-year-outcomes/ArticleStandard/Article/detail/624469?contextCategoryId=9395&ref=25 Two large studies of cryoablation for prostate cancer showed positive disease-free rates. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624469null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/PSA-kinetics-Not-a-reliable-signal-to-intervene/ArticleStandard/Article/detail/624463?contextCategoryId=9395&ref=25 PSA velocity and PSA doubling time, once considered promising tools for identifying the need for intervention in prostate cancer patients under active surveillance, now appear to have failed to meet that promise. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624463null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Estrogen-receptor-modulator-reduces-ADT-fractures/ArticleStandard/Article/detail/624483?contextCategoryId=9395&ref=25 Androgen deprivation therapy leads to an increased risk of bone fractures and other side effects of estrogen deficiency in men with prostate cancer, but those effects can be successfully treated with the use of an oral selective estrogen receptor modulator, suggest the results of a large, prospective, randomized tria presented at the AUA annual meeting in Chicago. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624483null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Radiotherapy-well-tolerated-in-pre-radical-prostat/ArticleStandard/Article/detail/614283?contextCategoryId=9395&ref=25 Planned radical prostatectomy within 8 weeks of preoperative radiotherapy is well tolerated and may result in downstaging of the disease, according to results of a phase I study. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614283null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Lower-payment-not-only-factor-in-dropping-LHRH-usa/ArticleStandard/Article/detail/614301?contextCategoryId=9395&ref=25 The substantial decrease in the use of LHRH agonists in the U.S. since 2004 may not be entirely explained by a recent reduction in physician reimbursement. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614301null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Base-International-Index-of-Erectile-Function-scor/ArticleStandard/Article/detail/614286?contextCategoryId=9395&ref=25 A study by psychologists and urologists has found that factors affecting erectile function after prostatectomy have much the same impact after other prostate cancer treatments. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614286null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Study-Cure-rate-of-80-seen-with-male-sling/ArticleStandard/Article/detail/614288?contextCategoryId=9395&ref=25 A non-bone-anchored male sling appears to resolve mild to moderate post-prostatectomy incontinence in up to 80% of patients and may also lead to significant improvement in erectile and sexual function. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614288null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Post-radical-prostatectomy-expectations-about-sexu/ArticleStandard/Article/detail/614300?contextCategoryId=9395&ref=25 A significant number of patients undergoing open or robotic radical prostatectomy have unrealistic expectations about postoperative sexual function. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614300null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Post-radical-prostatectomy-margin-location-may-aff/ArticleStandard/Article/detail/614289?contextCategoryId=9395&ref=25 A solitary positive apical margin following radical prostatectomy is associated with a higher biochemical recurrence rate than are negative surgical margins., but positive apical margins are associated with a lower recurrence rate than non-apical or multifocal positive margins are. 2009-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/312009/614289null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/CaPSURE-registry-reveals-radical-prostatectomys-su/ArticleStandard/Article/detail/606039?contextCategoryId=9395&ref=25 Data from a large registry of men with localized prostate cancer suggest better outcomes for radical prostatectomy compared to other therapies when either cancer-specific or overall mortality is the outcome. 2009-07-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/262009/606039null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Prostate-cancer-research-Officials-say-funding-mus/ArticleStandard/Article/detail/602358?contextCategoryId=9395&ref=25 Prostate cancer research deserves the same level of government commitment that other forms of cancer receive, even those that affect young children. 2009-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/242009/602358null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Dutasteride-shown-to-reduce-prostate-cancer-in-hig/ArticleStandard/Article/detail/602361?contextCategoryId=9395&ref=25 Dutasteride (Avodart) reduces the risk of biopsy-detectable prostate cancer by about one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers. In addition, the 5-alpha-reductase inhibitor significantly enhances the utility of PSA as a diagnostic test for prostate cancer. 2009-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/242009/602361null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Immunotherapy-data-may-signal-new-era-in-advanced-/ArticleStandard/Article/detail/602364?contextCategoryId=9395&ref=25 Results of a milestone study on the use of an experimental form of immunotherapy may usher in a new era in the management of androgen-independent prostate cancer. 2009-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/242009/602364null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Prostate-cancer-chemoprevention-Whats-the-next-ste/ArticleStandard/Article/detail/602366?contextCategoryId=9395&ref=25 Further analysis of the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial will help answer important questions and direct therapy. 2009-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/242009/602366null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Conference+News/AUA-Advanced-prostate-cancer-drug-is-now-available/ArticleStandard/Article/detail/595079?contextCategoryId=9395&ref=25 Ferring Pharmaceuticals' novel treatment for advanced prostate cancer, degarelix, is available for use. 2009-04-26T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/172009/595079null HTML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Link-found-between-BRCA-mutations-advanced-prostat/ArticleStandard/Article/detail/593049?contextCategoryId=9395&ref=25 Results of a community-based case-control study show that men with prostate cancer carrying BRCA1 and BRCA2 founder mutations have an increased susceptibility to having advanced disease. 2009-04-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/152009/593049null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Cardiac-drug-may-interrupt-prostate-tumor-growth/ArticleStandard/Article/detail/593048?contextCategoryId=9395&ref=25 Findings from a series of preclinical studies show that digoxin (Lanoxin) can affect tumor biology and interfere with tumor growth and may provide a basis for conducting clinical trials to investigate a potential role of the drug in prostate and other cancers, said Gregg L. Semenza, MD, PhD. 2009-04-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/152009/593048null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-J/ArticleStandard/Article/detail/591107?contextCategoryId=9395&ref=25 In laboratories and surgical suites, urologists at Johns Hopkins University, Baltimore, are breaking new ground in prostate cancer research as well as setting improved quality standards of care. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591107null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591093?contextCategoryId=9395&ref=25 Number of patients treated/procedures performed per year – 1,200 radical prostatectomies performed in 2008. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591093null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence-ndash-Prostate-Canc/ArticleStandard/Article/detail/591088?contextCategoryId=9395&ref=25 Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic by the numbers 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591088null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Metabolite-fingerprints-linked-to-aggressive-prost/ArticleStandard/Article/detail/591099?contextCategoryId=9395&ref=25 Using a relatively novel approach to identify microalterations differentiating benign prostatic disease from clinically localized prostate cancer and its progression to metastatic disease, researchers at the University of Michigan have identified a series of metabolites that they believe hold promise for use as biomarkers of tumor aggressiveness and invasiveness. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591099null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591095?contextCategoryId=9395&ref=25 National Cancer Institute Specialized Program of Research Excellence (SPORE) in Prostate Cancer 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591095null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591094?contextCategoryId=9395&ref=25 Clinical Centers of Excellence - Prostate Cancer: Memorial Sloan-Kettering Cancer Center by the numbers 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591094null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-J/ArticleStandard/Article/detail/591091?contextCategoryId=9395&ref=25 Johns Hopkins' James Buchanan Brady Urological Institute in fiscal 2008 received $9 million in grants from the National Cancer Institute. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591091null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591105?contextCategoryId=9395&ref=25 The Memorial Sloan-Kettering Cancer Center Sidney Kimmel Center for Prostate and Urologic Cancers is striving to defeat metastatic prostate cancer through aggressive efforts in prevention, detection, diagnosis, research, and treatment. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591105null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Focal-therapy-may-be-viable-option-for-low-grade-p/ArticleStandard/Article/detail/591098?contextCategoryId=9395&ref=25 Focal therapy for prostate cancer has been surrounded by controversy due to the multifocal nature of the disease. Emerging evidence for a biologically dominant or index tumor, however, has the potential to shift the paradigm to focal therapy in carefully selected patients, according to experts speaking at the Medical Innovation Summit at Cleveland Clinic. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591098null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591106?contextCategoryId=9395&ref=25 Experienced clinicians, a broad range of treatment options, extensive and well-funded research, a large and comprehensive patient database, and a strong emphasis on collaboration make the Mayo Clinic's department of urology a Clinical Center of Excellence for the treatment of prostate cancer. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591106null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer/ArticleStandard/Article/detail/591103?contextCategoryId=9395&ref=25 The purpose of the Clinical Centers of Excellence series is to recognize those institutions that bring something extra to the specialty, whether through research, patient care, community outreach, or all of these areas. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591103null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-J/ArticleStandard/Article/detail/591090?contextCategoryId=9395&ref=25 Clinical Centers of Excellence - Prostate Cancer: Johns Hopkins University by the numbers 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591090null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence-ndash-Prostate-Canc/ArticleStandard/Article/detail/591089?contextCategoryId=9395&ref=25 Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic – Selection criteria 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591089null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-C/ArticleStandard/Article/detail/591104?contextCategoryId=9395&ref=25 Cleveland Clinic has a history of pioneering innovation and leading-edge research in urology. Prostate cancer is no exception. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591104null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Clinical-Centers-of-Excellence---Prostate-Cancer-M/ArticleStandard/Article/detail/591092?contextCategoryId=9395&ref=25 Clinical Centers of Excellence - Prostate Cancer: Mayo Clinic by the numbers 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591092null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Solo-epothilone-yields-21-response-rate-in-androge/ArticleStandard/Article/detail/584407?contextCategoryId=9395&ref=25 First-line treatment with a novel agent known as sagopilone yields a high response rate and substantial decline in PSA in men with androgen-independent prostate cancer, according to findings presented at the European Society for Medical Oncology 33rd Congress. 2009-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/102009/584407null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Prostate-specific-antigen-standardization-Making-s/ArticleStandard/Article/detail/584398?contextCategoryId=9395&ref=25 Efforts to standardize PSA assays were undertaken a decade ago, but PSA standardization remains controversial. 2009-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/102009/584398null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Pre-radical-prostatectomy-leakage-pad-use-predicts/ArticleStandard/Article/detail/584390?contextCategoryId=9395&ref=25 Baseline urinary continence status, based on a strict definition of no leakage or pad use, is predictive of improved return of continence following radical prostatectomy, according to University of Chicago researchers. 2009-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/102009/584390null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Studies-shed-light-on-erectile-function-in-prostat/ArticleStandard/Article/detail/577865?contextCategoryId=9395&ref=25 Erectile dysfunction is a fact of life for many men who receive treatment for prostate cancer, but methods of measuring post-treatment ED and erectile function recovery suffer from a lack of standardization, according to studies presented at the Sexual Medicine Society of North America 2008 Fall Scientific Meeting. 2009-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052009/577865null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Is-bisphenol-A-to-blame-for-rise-in-male-anomalies/ArticleStandard/Article/detail/577876?contextCategoryId=9395&ref=25 A material used in plastic baby bottles and other products, which has been associated with such health risks as reproductive system abnormalities, prostate cancer, and obesity, could be banned this year, according to a professor at the University of Missouri, Columbia. 2009-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052009/577876null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Testosterone-replacement-therapy-The-focus-is-shif/ArticleStandard/Article/detail/577863?contextCategoryId=9395&ref=25 Hypogonadism, or low serum testosterone, is associated with the unpleasant sequelæ of fatigue, low sex drive, diminished erections, and an increased tendency for fractures due to decreased bone mineral density. 2009-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052009/577863null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Testosterone-replacement-therapy-may-be-viable-tre/ArticleStandard/Article/detail/577877?contextCategoryId=9395&ref=25 Testosterone replacement in men with prostate cancer is a viable treatment option to improve their vitality, according to several studies presented at the Sexual Medicine Society of North America 2008 Fall Scientific Meeting. 2009-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052009/577877null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Post-radical-prostatectomy-patients-report-satisfa/ArticleStandard/Article/detail/577866?contextCategoryId=9395&ref=25 Men who turn to intracavernosal injection (ICI) therapy following prostate surgery can generate a satisfactory rigid erection with as few as five practice (trial) injections, according to studies presented at the 2008 Fall Scientific Meeting of the Sexual Medicine Society of North America. 2009-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052009/577866null XML http://www.modernmedicine.com/modernmedicine/CME+Showcase/Individualizing-Cancer-Care-in-the-Era-of-Evidence/ArticleStandard/Article/detail/587038?contextCategoryId=9395&ref=25 2008-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112009/587038null REMOTE http://www.modernmedicine.com/modernmedicine/Surgery/Optimizing-erectogenic-outcomes-during-athermal-ro/ArticleStandard/Article/detail/562086?contextCategoryId=9395&ref=25 This article describes a risk-stratified approach based on a three-zone anatomic layout to the periprostatic neural architecture and a modified athermal robotic technique for better continence and potency outcomes without compromising surgical margin rates. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442008/562086null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Multimodal-therapy-extends-survival-in-node-positi/ArticleStandard/Article/detail/563875?contextCategoryId=9395&ref=25 Lymph node-positive prostate cancer is not always indicative of systemic disease. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563875null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Post-radical-prostatectomy-incontinence-How-to-con/ArticleStandard/Article/detail/563891?contextCategoryId=9395&ref=25 Many post-prostatectomy incontinence patients have concomitant sphincteric and bladder dysfunctions. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563891null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Higher-dose-radiation-therapy-does-not-raise-toxic/ArticleStandard/Article/detail/563888?contextCategoryId=9395&ref=25 Increasing the radiation dose for better local control of prostate cancer does not increase long-term toxicity. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563888null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Tamoxifen-eases-androgen-deprivation-therapy-relat/ArticleStandard/Article/detail/563872?contextCategoryId=9395&ref=25 The 20-milligrams per day tamoxifen therapy reduced the severity of androgen deprivation therapy-related symptoms in prostate cancer patients. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563872null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/External-beam-radiation-therapy-patients-may-have-/ArticleStandard/Article/detail/563876?contextCategoryId=9395&ref=25 Prostate cancer patients who received radiation therapy were almost twice as likely to develop a secondary malignancy. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563876null XML http://www.modernmedicine.com/modernmedicine/Pathology/Results-bolster-diagnostic-value-of-prostate-cance/ArticleStandard/Article/detail/563877?contextCategoryId=9395&ref=25 The prostate cancer biomarker TMPRSS2-ERG is superior to DNA-based assays. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563877null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Infertile-males-at-higher-risk-for-melanoma-prosta/ArticleStandard/Article/detail/563878?contextCategoryId=9395&ref=25 Risks of developing melanoma and prostate cancer are increased among those with a diagnosis of male factor infertility. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563878null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Intermittent-androgen-deprivation-therapy-limits-s/ArticleStandard/Article/detail/563869?contextCategoryId=9395&ref=25 Intermittent androgen deprivation with a luteinizing hormone-releasing hormone analog causes fewer side effects and preserves quality of life compared with continuous combined androgen ablation, and many patients have prolonged treatment-free intervals. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563869null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Androgen-receptor-activity-suggests-androgen-depri/ArticleStandard/Article/detail/563871?contextCategoryId=9395&ref=25 Determining androgen receptor activity in castration-resistant prostate cancer may have potential for distinguishing patients who will respond to androgen deprivation from those who will not. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563871null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/New-prostate-specific-antigen-guidelines-to-tackle/ArticleStandard/Article/detail/563873?contextCategoryId=9395&ref=25 The 2008 update of the American Urological Association clinical guidelines for prostate-specific antigen screening will build on the 2000 version while addressing some controversial aspects of screening. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563873null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Prostate-cancer-survival-prolonged-with-thalidomid/ArticleStandard/Article/detail/563870?contextCategoryId=9395&ref=25 In men with nonmetastatic prostate cancer treated with intermittent androgen deprivation, thalidomide (Thalomid) significantly prolonged progression-free survival compared with placebo. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563870null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Phosphodiesterase-5-inhibitor-use-highest-after-la/ArticleStandard/Article/detail/563874?contextCategoryId=9395&ref=25 Radical prostatectomy patients are most likely to use medication for erectile dysfunction after surgery; those who underwent laparoscopic/robotic prostatectomy were most likely to use ED drugs. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563874null XML http://www.modernmedicine.com/modernmedicine/Surgery/Myth-of-lower-morbidity-for-laparoscopic-radical-p/ArticleStandard/Article/detail/557217?contextCategoryId=9395&ref=25 Complications after laparoscopic radical prostatectomy demonstrates the effect of a learning curve and the benefits of improved surgical technique, but shows little difference in overall morbidity when compared with those of anatomic radical retropubic prostatectomy . 2008-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/412008/557217null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/EPCA-2-validated-as-serum-prostate-cancer-marker/ArticleStandard/Article/detail/557226?contextCategoryId=9395&ref=25 EPCA-2.19, a second, independent epitope of the EPCA-2 protein, offers extremely high sensitivity and specificity results that are almost identical to those obtained for a first published assay using the EPCA-2.22 epitope. 2008-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/412008/557226null XML http://www.modernmedicine.com/modernmedicine/Surgery/Image-guidance-helps-enhance-robotic-surgery/ArticleStandard/Article/detail/557219?contextCategoryId=9395&ref=25 Incorporating image guidance into robotic surgery significantly enhanced tumor resection in a series of mock procedures involving surgical phantoms 2008-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/412008/557219null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/PCA3-data-suggest-new-cutoffs-value-vs-prostate-sp/ArticleStandard/Article/detail/557223?contextCategoryId=9395&ref=25 In the search for novel biomarkers for prostate cancer diagnosis, a urinary assay for prostate cancer gene 3 (PCA3) has emerged as a promising modality. 2008-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/412008/557223null XML http://urologytimes.modernmedicine.com/urologytimes/News/Male-immigrants-face-US-prostate-cancer-risks/ArticleStandard/Article/detail/552220?contextCategoryId=9395&ref=25 When men and women from India and Pakistan migrate to the United States, their disease profiles change, mirroring the American risk. 2008-09-25T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392008/552220null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/PSA-screening-awareness-needed-among-high-risk-gro/ArticleStandard/Article/detail/548456?contextCategoryId=9395&ref=25 One-fifth of men under age 50 reported undergoing a PSA test to detect prostate cancer in the previous year, yet only one in three young African-American men reported ever having had a PSA test in the previous year, according to researchers at the Duke University Prostate Center (Durham, NC). The findings appear in the June 23 online edition of Cancer and will appear in the Sept. 15 print edition. 2008-09-11T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548456null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Obese-PCa-patients-may-benefit-more-from-brachythe/ArticleStandard/Article/detail/548457?contextCategoryId=9395&ref=25 Brachytherapy may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2008; 71:1302-8). 2008-09-11T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548457null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Second-phase-II-trial-of-PCa-immunotherapy-begins/ArticleStandard/Article/detail/548459?contextCategoryId=9395&ref=25 Dendreon Corp. has initiated its second of two new phase II trials of sipuleucel-T (Provenge), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer. 2008-09-11T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548459null HTML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Novel-prostate-cancer-therapies-focus-on-multiple-/ArticleStandard/Article/detail/548551?contextCategoryId=9395&ref=25 A wide array of novel targeted prostate cancer therapies are in progress or planned for the very near future. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548551null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Bisphosphonate-during-androgen-deprivation-therapy/ArticleStandard/Article/detail/548548?contextCategoryId=9395&ref=25 Bone mineral density may increase by 6 percent or more after 1 year of bisphosphonate treatment in men who receive the therapy soon after hormone deprivation therapy is initiated and in men who have been on the therapy for a year or longer. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548548null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Research-sets-stage-for-subtotal-focal-ablation-of/ArticleStandard/Article/detail/548568?contextCategoryId=9395&ref=25 Patients with low-risk prostate cancer, whether ulilateral or bilateral, may be considered for focal ablative therapy. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548568null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Debate-intensifies-over-prostate-specific-antigen-/ArticleStandard/Article/detail/548552?contextCategoryId=9395&ref=25 There are no high-level data to support current screening practices for PSA in men of any age, particularly in older men with a shorter life expectancy. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548552null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Multiple-studies-support-diets-effect-on-prostate-/ArticleStandard/Article/detail/548553?contextCategoryId=9395&ref=25 Studies suggest that diet can have a significant impact on the incidence, progression, and mortality of prostate cancer. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548553null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/New-gonadotropin-releasing-hormone-blocker-quickly/ArticleStandard/Article/detail/548558?contextCategoryId=9395&ref=25 An investigational gonadotropin-releasing hormone blocker produces an almost immediate reduction in the testosterone levels of patients undergoing treatment for prostate cancer. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548558null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/High-rate-of-prostate-cancer-found-in-post-radiati/ArticleStandard/Article/detail/548560?contextCategoryId=9395&ref=25 Viable prostate cancer was detected on histologic examination of the surgical specimen from about half of patients who underwent radical cystoprostatectomy for nonprostate cancer-related disease after having received definitive radiation therapy for localized prostate cancer. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548560null XML http://www.modernmedicine.com/modernmedicine/Kidney+%26+Bladder+Cancer/Prostate-cancer-radiotherapy-raises-bladder-rectal/ArticleStandard/Article/detail/548549?contextCategoryId=9395&ref=25 Men who receive some form of radiotherapy for localized prostate cancer have an elevated risk of later developing bladder and rectal cancers. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548549null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Study-shows-good-long-term-cancer-control-with-lap/ArticleStandard/Article/detail/548559?contextCategoryId=9395&ref=25 Laparoscopic radical prostatectomy for clinically localized prostate cancer is associated with very good long-term oncologic control. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548559null XML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Study-refutes-beliefs-about-young-prostate-cancer-/ArticleStandard/Article/detail/548550?contextCategoryId=9395&ref=25 Young men diagnosed with prostate cancer are more likely to have aggressive disease and better progression-free survival than older men. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548550null XML http://www.modernmedicine.com/modernmedicine/Perspective/Subtotal-focal-therapy-for-prostate-cancer-Not-rea/ArticleStandard/Article/detail/548565?contextCategoryId=9395&ref=25 Focal cryotherapy, defined as less than complete ablation of the prostate gland with ice, potentially offers targeted local cancer control, preserving sexual potency and urinary continence in patients whose cancer is believed to be unilaterally clinically significant. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548565null XML